Studying SHR-1139 for pyoderma gangrenosum ulcers
Part of Skin clinical trials.
This trial tests an injection called SHR-1139 for people with pyoderma gangrenosum (a rare skin condition that causes painful ulcers). If you have at least one ulcer that is 5 cm² or larger and your PARACELSUS score is at least 10, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with ulcerative pyoderma gangrenosum with a PARACELSUS score of 10 or higher.
- You have at least one PG ulcer that is at least 5 cm² (about the size of a large coin) at the start of the study.
- You are willing to use effective birth control (if you or your partner could become pregnant) and don't plan to donate sperm or eggs during the study.
- You do not have active cancer (except certain skin cancers treated successfully) or a history of lymphoma.
- Your PG ulcer does not have an active infection and is not a chronic wound that won't respond to treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called SHR-1139 for adult patients with ulcerative pyoderma gangrenosum (a type of painful skin ulcer). The goal is to see if the drug is safe and helps heal the ulcers.
This trial tests whether the drug spesolimab can help people with a skin condition called pyoderma gangrenosum, which causes painful ulcers. It's for adults who have at least one active ulcer that's at least 2 inches across and needs treatment.
This study tests whether guselkumab (Tremfya) can help heal painful ulcers from Pyoderma Gangrenosum (PG). Participants must already be taking steroid medication and have a PG ulcer that is at least 4 cm².
This study tests whether the drug bimekizumab can help heal ulcers caused by a rare skin condition called pyoderma gangrenosum (PG). If you have PG and are already taking prednisone, this trial may offer a new treatment option.
This study tests a cream called ruxolitinib for people with pyoderma gangrenosum, a condition that causes painful skin ulcers. The cream is applied directly to the ulcer, and the study aims to see if it helps heal the wounds.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
Hear when a new Pyoderma Gangrenosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.